Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
IL-23 inhibitors
7 evidence topics · 9 sources
Biologics guideline: recommendations for guselkumab and tildrakizumab
Guselkumab: FDA-approved indication, dosage, and week 16 outcomes in Trials PsO1 and PsO2
| Outcome at Week 16, n (%) | Trial PsO1 placebo (N=174) | Trial PsO1 TREMFYA (N=329) | Trial PsO2 placebo (N=248) | Trial PsO2 TREMFYA (N=496) |
|---|---|---|---|---|
| IGA response of 0/1 | “12 (7)” | “280 (85)” | “21 (8)” | “417 (84)” |
| PASI 90 response | “5 (3)” | “241 (73)” | “6 (2)” | “347 (70)” |
Risankizumab: FDA-approved indication, dosage, and week 16 and week 52 outcomes in PsO-1 and PsO-2
| Outcome at Week 16, n (%) | PsO-1 SKYRIZI (N=304) | PsO-1 placebo (N=102) | PsO-2 SKYRIZI (N=294) | PsO-2 placebo (N=98) |
|---|---|---|---|---|
| sPGA 0 or 1 | “267 (88)” | “8 (8)” | “246 (84)” | “5 (5)” |
| PASI 90 | “229 (75)” | “5 (5)” | “220 (75)” | “2 (2)” |
| PASI 100 | “109 (36)” | “0 (0)” | “149 (51)” | “2 (2)” |
Tildrakizumab: FDA-approved indication, dosage, and week 12 outcomes in Trials 2 and 3
| Outcome at Week 12, n (%) | Trial 2 ILUMYA 100 mg (N=309) | Trial 2 placebo (N=154) | Trial 3 ILUMYA 100 mg (N=307) | Trial 3 placebo (N=156) |
|---|---|---|---|---|
| PGA of 0 or 1 | “179 (58)” | “11 (7)” | “168 (55)” | “7 (4)” |
| PASI 75 | “197 (64)” | “9 (6)” | “188 (61)” | “9 (6)” |
| PASI 90 | “107 (35)” | “4 (3)” | “119 (39)” | “2 (1)” |
Decision aid: IL-23 inhibitors
| Agent | Roughly what proportion of people are clear or nearly clear (PASI 90) in the first 6 months? | What is the likelihood of staying on this treatment for more than 1 year? |
|---|---|---|
| Guselkumab | “44%” | “85–90% chance” |
| Risankizumab | “51%” | “Not known at present” |
| Tildrakizumab | “32%” | “Not known at present” |
Network meta-analyses: anti-IL-23 agents, adverse events, and short-term and long-term PASI 90
“Placebo had the highest SUCRA (SUCRA 93.9) at class‐level for all adverse events, followed by anti‐IL23 (versus placebo: RR 1.01, 95% CI 0.95 to 1.06; SUCRA = 89.9), anti‐TNF agents (versus placebo: RR 1.08, 95% CI 1.03 to 1.13; SUCRA = 61.3), and anti‐IL12/23 (versus placebo: RR 1.08, 95% CI 1.01 to 1.14; SUCRA = 60.8).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At class level, all treatment classes showed evidence of a higher risk of adverse events compared to placebo, except for anti‐IL23.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“guselkumab was more effective than adalimumab in reaching PASI 90 at 52 weeks (RR 1.59, 95% CI 1.40 to 1.81)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At weeks 44 to 60, the treatments with the highest PASI 90 rates were risankizumab-rzaa (79.4%, 95% CI, 75.5%-82.9%), guselkumab (76.5%; 95% CI, 72.1%-80.5%), brodalumab (74.0%; 95% CI, 69.3%-78.1%), and ixekizumab (73.9%; 95% CI, 69.9%-77.5%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Treatment | PASI 75 at 10 to 16 weeks, % (95% CrI) | PASI 90 at 10 to 16 weeks, % (95% CrI) | PASI 100 at 10 to 16 weeks, % (95% CrI) |
|---|---|---|---|
| Risankizumab-rzaa, 150 mg | “89.2 (86.9-91.3)”View highlighted excerpt for this quote | “71.6 (67.5-75.4)”View highlighted excerpt for this quote | “40.4 (35.9-45.0)”View highlighted excerpt for this quote |
| Guselkumab, 100 mg | “86.8 (83.8-89.4)”View highlighted excerpt for this quote | “67.3 (62.5-71.9)”View highlighted excerpt for this quote | “35.7 (30.9-40.7)”View highlighted excerpt for this quote |
| Tildrakizumab-asmn, 100 mg | “62.9 (57.3-68.4)”View highlighted excerpt for this quote | “36.8 (31.4-42.5)”View highlighted excerpt for this quote | “12.5 (9.7-15.8)”View highlighted excerpt for this quote |
Drug survival and switching risk with IL-23 inhibitors compared with other biologics
“Among 19,034 treatment courses (median follow‐up: 2.3 years), treatments included adalimumab (tumour necrosis factor‐alpha (TNF‐a) inhibitor, n = 6,815), ustekinumab (IL‐12/23p40 inhibitor, n = 5,639), secukinumab (IL‐17A inhibitor, n = 3,051), ixekizumab (IL‐17A inhibitor, n = 1,072), brodalumab (n = 367), guselkumab (IL‐23p19 inhibitor, n = 1,258) and risankizumab (n = 832).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Guselkumab and risankizumab had the highest adjusted survival times (years [interquartile ranges]) for effectiveness (1.93 [1.91–1.95] and 1.93 [1.90–1.96], respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“IL-23 inhibitors were associated with the lowest risk of switching compared with TNF, IL-17, and IL-12/23 inhibitors over 24 months (p < 0.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Switch rates varied between specific biologics, with the lowest switch rates observed for patients treated with risankizumab at 8.5% followed by guselkumab at 15.7% over 24 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote